A Phase II Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2018
Price : $35 *
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Brain metastases; Breast cancer; Lung cancer
- Focus Therapeutic Use
- Acronyms CaBaMet
- 19 Jan 2018 Status changed from suspended to discontinued.
- 26 Jun 2017 Planned End Date changed from 1 Sep 2017 to 1 Apr 2018.
- 06 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Apr 2017.